GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Float Percentage Of Total Shares Outstanding

ZYUS Life Sciences (TSXV:ZYUS) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 20, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ZYUS Life Sciences's float shares is 0.00 Mil. ZYUS Life Sciences's total shares outstanding is 70.85 Mil. ZYUS Life Sciences's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ZYUS Life Sciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ZYUS Life Sciences's Institutional Ownership is 0.23%.


ZYUS Life Sciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ZYUS Life Sciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/70.85
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Industry
Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines